European CRO chooses USA-based Pharma Services Network to promote FIM, QTc, and other Phase 1 clinical trials to the American market

“BioKinetic provides First in Man (FIM), QTc, and other Phase 1 clinical trials in the UK for sponsors who are seeking rapid study startup, a familiar, English-speaking environment, and expertise in Women’s Health, Pain Management, Diabetes, and Oncology.  The UK is a great place for Phase 1 clinical research because of its 14-day regulatory approval cycle for studies,” says Moira Burke, Managing Director of BioKinetic Europe.

“Our team of experienced Life Science physicians and clinicians has conducted clinical research for many of the top American pharmaceutical companies.  Now, with a representative office and AmeriStart’s organizational support, we hope to expand and improve our standing in the US marketplace.”

AmeriStart CEO Jim Worrell noted, “BioKinetic Europe is a world-class experienced CRO, and because of their location, can get regulatory approval for a study in just 14 days.  This speed is important to sponsors – now more than ever.  In today’s economy, compressing regulatory and development timelines is often key to keeping investors engaged.”

In addition to ICH GCP compliance, BioKinetic Europe operates within the UK (MHRA) and EU (EMEA) regulatory frameworks. The company has successfully completed both MHRA GCP and GMP inspections and has been awarded Supplementary Accreditation status in April 2009. BioKinetic also holds a current Manufacturing Authorization for IMP, which includes vaccines.

BioKinetic is the latest addition to the AmeriStart portfolio of world-class Contract Research Organizations (CROs) and other service providers to the Life Science industry.

About BioKinetic

BioKinetic, established in 1996, is a woman-owned Contract Research Organization offering regulatory and clinical trial services for Pharmaceutical and Biotech sponsors from headquarters in Northern Ireland, UK.